Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
mycophenolic acid 2 nephrologydiseasesdrugs
rituximab 1 nephrologydiseasesdrugs
tacrolimus 2 nephrologydiseasesdrugs

There are not enough annotations found in this document to create the proximity graph.


Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
mycophenolic acid 13349 [[58]].2.2. Mycophenolate Mofetil (MMF)MMF is a prodrug that is rapidly hydrolyzed to the active metabolite, mycophenolic acid (MPA), and acts by blocking nucleic acid synthesis through potent, selective, noncompetitive inhibition
mycophenolic acid 13967 the “salvage” pathway, which is not inhibited by MPA [[59]].MPA is metabolized to inactive 7-O- mycophenolic acid MPA glucuronide (MPAG) via hepatic UDP-glucuronosyltransferase (UGT), particularly UGT1A9, and is then
rituximab 32002 in patients who have such an infiltration, early treatment with a monoclonal antibody against CD20 ( rituximab ) could be beneficial.Subsequently, a similar methodological approach has been undertaken to recognize
tacrolimus 7560 Micophenolic acid; MMF: Mycophenolate mofetil.2.1. Calcineurin Inhibitors (CNIs)CNIs, cyclosporin A (CsA) and tacrolimus (TAC), currently employed as the backbone of most immunosuppressive regimens in renal transplantation,
tacrolimus 12802 polymorphism is associated with better long-term renal function [[57]].However, although most of the tacrolimus -related pharmacogentic studies are encouraging, the only published randomized controlled-study using
Select Disease Character Offset Disease Term Instance

You must be authorized to submit a review.